Back to Clinical Trials
N/ARecruiting

Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension

Sponsored by Tempus AI

About this study

MOMENTOUS is a multi-center, randomized study to prospectively evaluate the performance of an ECG-based AI device to predict whether participants with interstitial lung disease (ILD) are at high risk of undiagnosed pulmonary hypertension.

The goal of this study is to evaluate the use of an ECG-based AI device that may help predict if participants with interstitial lung disease (ILD) are at high risk of undiagnosed pulmonary hypertension (PH). The study seeks to determine whether use of the device increases the rate of new PH diagnoses over a period of 6 months as compared to current standard of care. The study will recruit participants with ILD from lung disease clinics who will each receive a 12-lead ECG (a test that measures the electrical activity of the heart) following consent. The device will analyze the 12-lead ECG results to identify participants that are at high risk of having undiagnosed PH. Participants will be randomly assigned to either the Device or Control group. For participants in the Device group investi…

Where this study is enrolling (35)

  • University of Alabama at Birmingham

    Birmingham, Alabama

    I'm interested

  • Banner University Medical Center

    Phoenix, Arizona

    I'm interested

  • Dignity Health - St. Joseph's Hospital and Medical Center-Norton Thoracic Institute

    Phoenix, Arizona

    I'm interested

  • HCA Riverside Community Hospital

    Riverside, California

    I'm interested

  • National Jewish Health

    Denver, Colorado

    I'm interested
Show all 35 locations
Who can participate

Inclusion criteria

  • ✓18 years or older at the time of consent
  • ✓A known diagnosis of interstitial lung disease
  • ✓Diffusing capacity for carbon monoxide (DLCO) \<30% predicted, collected within 6 months prior to consent
  • ✓Willing and able to provide informed consent and undergo all study-specific procedures, including echo and RHC, if required

Exclusion criteria

  • ✕A known diagnosis of pulmonary hypertension (including patients prescribed a therapy specifically for pulmonary arterial hypertension (PAH))
  • ✕A RHC was completed within the previous 1 year or ordered and not yet completed at the time of consent
  • ✕LV ejection fraction ≤ 40% on most recent echo or cardiac MRI, if available
  • ✕Unclassifiable Tempus PH ECG risk result after up to 2 ECG acquisitions
  • ✕A contraindication to RHC exists (for example, pregnancy or mechanical right heart valve)
  • ✕Physician decision that if a patient is directed to RHC by the study protocol, the potential risks of RHC outweigh the potential benefits
  • ✕There is a severe concomitant illness limiting life expectancy to less than 6 months (at the discretion of the investigator)
  • ✕There is a medical or social factor that makes the patient a poor candidate for the study and/or unlikely to be able to comply with the study protocol or complete study procedures (at the discretion of the investigator)

Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.

Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.

Trial data sourced from ClinicalTrials.gov.